Stevens-Johnson Syndrome

Stevens-Johnson Syndrome (SJS): A Comprehensive Clinical Overview

Stevens-Johnson Syndrome (SJS) represents a rare, acute, and potentially life-threatening mucocutaneous reaction. It is classified as a severe cutaneous adverse reaction (SCAR) characterized by extensive necrosis and detachment of the epidermis. Clinically, SJS is considered a variant on a spectrum with Toxic Epidermal Necrolysis (TEN), categorized primarily by the percentage of body surface area (BSA) involved.

Clinical Definition and Classification

The consensus classification for SJS/TEN spectrum is based on the extent of epidermal detachment:
* SJS: Less than 10% BSA detachment.
* SJS/TEN Overlap: 10% to 30% BSA detachment.
* T Greater than 30% BSA detachment.

This condition is a medical emergency requiring immediate withdrawal of the offending agent and admission to a specialized burn unit or intensive care unit (ICU).

Etiology and Pathophysiology

The Triggering Mechanism

The pathogenesis of SJS is a complex, immune-mediated process. It is primarily a delayed-type hypersensitivity reaction (Type IV) triggered by medications. The mechanism involves the activation of cytotoxic T-lymphocytes and Natural Killer (NK) cells.

Key Pathophysiological Steps

1. Drug Metabolism/Haptens: The offending drug or its metabolites act as haptens, binding to endogenous proteins and presenting them as "foreign" to the immune system.
2. T-Cell Activation: CD8+ cytotoxic T-cells and NK cells are activated, releasing high concentrations of granulysin, perforin, and granzyme B.
3. Keratinocyte Apoptosis: The release of granulysin is the primary driver of massive keratinocyte apoptosis (programmed cell death).
4. Fas-FasL Interaction: The interaction between the Fas receptor on keratinocytes and the Fas-ligand (FasL) expressed by immune cells further propagates the apoptotic cascade.
5. Epidermal Detachment: As keratinocytes die, the epidermal-dermal junction is compromised, leading to the clinical hallmark of skin sloughing.

Common Precipitating Agents

High-risk medications include:
* Anti-epileptics: Carbamazepine, Phenytoin, Lamotrigine, Phenobarbital.
* Antibiotics: Sulfonamides (e.g., Sulfamethoxazole), Penicillins, Cephalosporins, Quinolones.
* NSAIDs: Oxicams (e.g., Piroxicam).
* Allopurinol: A common trigger, particularly in patients with specific HLA genotypes.

Clinical Presentation and Staging

Prodromal Phase

SJS typically begins with a non-specific prodrome lasting 1 to 3 days before the onset of skin lesions. Symptoms include:
* High-grade fever.
* Malaise and myalgia.
* Sore throat and rhinitis.
* Burning sensation in the eyes.

Cutaneous and Mucosal Manifestations

The skin lesions typically start as erythematous macules that progress to atypical targets—lesions with a dark, purpuric center that may blister.
* Mucosal Involvement: Present in over 90% of cases. It involves the oral, ocular, and genital mucosa.
* Oral: Painful erosions, crusting of the lips, and difficulty swallowing.
* Ocular: Conjunctivitis, photophobia, and corneal ulcerations.
* Genital: Painful erosions, urethritis, and vaginal synechiae.

The SCORTEN Scale

To assess prognosis and mortality risk, clinicians use the SCORTEN (SCORE of Toxic Epidermal Necrolysis) system, calculated within 24 hours of admission.

Differential Diagnosis

Distinguishing SJS from other blistering disorders is vital for management.

1. Erythema Multiforme (EM) Major: Often confused with SJS. EM is usually triggered by Herpes Simplex Virus (HSV) rather than drugs and typically presents with "true" target lesions (three zones of color) on extremities.
2. Staphylococcal Scalded Skin Syndrome (SSSS): Primarily affects infants/children. It involves cleavage at the granular layer (superficial), whereas SJS involves the full epidermal-dermal junction.
3. Acute Generalized Exanthematous Pustulosis (AGEP): Characterized by numerous small, sterile pustules on an erythematous base.
4. Pemphigus Vulgaris: An autoimmune blistering disease with positive Nikolsky sign, but usually without the systemic prodrome or drug-trigger history seen in SJS.

Diagnostic Procedures and Testing

• Skin Biopsy: The gold standard. Histopathology reveals full-thickness epidermal necrosis and a sparse lymphocytic infiltrate at the dermo-epidermal junction.
• Nikolsky Sign: Gently rubbing the skin results in separation of the epidermis from the dermis (indicates severe loss of adhesion).
• Laboratory Evaluation: CBC (lymphopenia is common), metabolic panel (to monitor renal/hepatic function), and cultures (blood/skin) to rule out sepsis.

Management and Treatment

Management is primarily supportive.

1. Immediate Drug Withdrawal: The most critical step.
2. Fluid and Electrolyte Replacement: Managed similarly to severe burn patients to prevent hypovolemic shock.
3. Wound Care: Use of non-adherent dressings, topical antiseptics, and avoidance of systemic steroids (which may increase infection risk).
4. Ophthalmology Consultation: Mandatory for all SJS patients to prevent long-term ocular scarring and blindness.
5. Immunomodulatory Therapies: While debated, some centers utilize IVIG (Intravenous Immunoglobulin), Cyclosporine, or Etanercept to arrest the apoptotic process.

Risks, Side Effects, and Long-Term Prognosis

Acute Complications

• Sepsis and multi-organ failure.
• Severe dehydration and electrolyte imbalance.
• Respiratory distress (if bronchial mucosa is involved).

Long-Term Sequelae

• Ocular: Chronic dry eye, symblepharon (adhesion of eyelids to the eyeball), corneal scarring, and trichiasis (ingrown eyelashes).
• Dermatological: Post-inflammatory hyperpigmentation, scarring, and nail dystrophy.
• Psychological: Post-traumatic stress disorder (PTSD) due to the severity of the illness.

Frequently Asked Questions (FAQ)

1. Is SJS contagious?

No, SJS is not contagious. It is an immune-mediated hypersensitivity reaction to drugs or, less commonly, infections.

2. Can SJS be prevented?

Prevention involves avoiding known offending drugs. In certain populations (e.g., Han Chinese patients), genetic screening for HLA-B*15:02 is recommended before starting Carbamazepine to reduce SJS risk.

3. What is the difference between SJS and TEN?

The difference is the extent of skin detachment. SJS involves <10% BSA, while TEN involves >30% BSA.

4. How long does the recovery process take?

The acute phase usually lasts 2–4 weeks. Complete re-epithelialization can take several weeks, but long-term ocular or skin complications may persist for years.

5. Why are systemic steroids controversial?

While they suppress inflammation, studies have shown that high-dose systemic steroids may increase the risk of secondary infections and sepsis in SJS/TEN patients.

6. Is SJS hereditary?

While there is no direct inheritance, certain genetic predispositions (HLA types) make individuals more susceptible to drug-induced hypersensitivity.

7. Does the skin grow back to normal?

In many cases, the skin heals well, but patients may experience pigment changes, sensitivity, or scarring. Mucosal areas are more prone to permanent scarring.

8. What is the role of the ophthalmologist in SJS?

They monitor for corneal abrasions and synechiae. They may apply amniotic membrane grafts to the ocular surface to preserve vision.

9. Can SJS recur?

Yes, if the patient is re-exposed to the offending drug or a structurally similar agent (cross-reactivity).

10. What is the mortality rate of SJS?

The mortality rate for SJS is approximately 5–10%, whereas TEN carries a mortality rate of 25–30% or higher.

Summary for Clinical Practice

Stevens-Johnson Syndrome is a devastating condition that requires a multidisciplinary approach. Early recognition, prompt cessation of the causative medication, and aggressive supportive care in a specialized burn or ICU setting are the cornerstones of improving patient outcomes. As a clinician, maintaining a high index of suspicion in patients presenting with fever and painful mucocutaneous lesions after starting a new medication is essential for timely intervention.

Disclaimer: This guide is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.